The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Abstract
Purpose: The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies. We report final analyses from the French Polycythemia Study Group (FPSG) study, which randomly assigned HU versus pipobroman as first-line therapy in 285 patients younger than age 65 years. Patients and Methods: The full methodology has been described previously. FPSG results were updated with a median follow-up of 16.3 years. Statistical analysis was performed by using competing risks on the intention-to-treat population and according to main treatment received. Results: Median survival was 17 years for the whole cohort, 20.3 years for the HU arm, and 15.4 years for the pipobroman arm (P = .008) and differed significantly from that in the general population. At 10, 15, and 20 years, cumulative incidence of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was 6.6%, 16.5%, and 24% in the HU arm and 13%, 34%, and 52% in the pipobroman arm (P = .004). Cumulative myelofibrosis incidence at 10, 15, and 20 years according to main treatment received was 15%, 24%, and 32% with HU versus 5%, 10%, and 21% with pipobroman (P = .02). Conclusion: Data from this unique randomized trial comparing HU with another cytoreductive drug in PV showed that (1) survival of patients with PV treated with conventional agents differed from survival in the general population, (2) evolution to AML/MDS is the first cause of death, (3) pipobroman is leukemogenic and is unsuitable for first-line therapy, and (4) incidence of evolution to AML/MDS with HU is higher than previously reported, although consideration should be given to the natural evolution of PV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationKiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Self-citationTherapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk, P. D., Goldberg, J. D., Donovan, P. B., Fruchtman, S. M., Berlin, N. I., & Wasserman, L. R. (1986) · PubMed · Cited by 493
Increased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil Therapy
Berk, P. D., Goldberg, J. D., Silverstein, M. N., Weinfeld, A., Donovan, P. B., Ellis, J. T., Landaw, S. A., Laszlo, J., Najean, Y., Pisciotta, A. V., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102193040801 · Cited by 492
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Passamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Brusamolino, E., Pascutto, C., et al. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.032 · Cited by 447
Finazzi, G. (2005) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 431
Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Cited by
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Myeloproliferative neoplasms and thrombosis
Barbui, T., Finazzi, G., & Falanga, A. (2013) · Blood · doi:10.1182/blood-2013-03-460154 · Cited by 415
Tefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 352
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Kubesova, B., Pavlova, S., Malcikova, J., Kabathova, J., Radova, L., Tom, N., Tichy, B., Plevova, K., Kantorova, B., Fiedorova, K., et al. (2018) · Leukemia · doi:10.1038/leu.2017.230 · Cited by 82
Metadata
- Authors
- Kiladjian, J.-J., Chevret, S., Dosquet, C., Chomienne, C., & Rain, J.-D.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-10-10
- Volume
- 29
- Issue
- 29
- Pages
- 3907-3913
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119941797
- Cited by
- 255
- References
- 17
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.